Throughout 18 months of follow-up, patients with PAD alone were markedly less likely to receive disease-modifying pharmacotherapy, consisting of oral antiplatelet therapy; blood pressure control, preferably with ACE inhibitors; and lipid control with statins, relative to patients with coronary artery disease [10]. This evidence concerns the gene ACE and peripheral arterial disease.